openPR Logo
Press release

Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global Industry Insights - 2025

02-05-2018 02:55 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Also, GLP-1 analogs provide weight reduction benefit.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1252

High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide. According to World Health Organization (WHO) report 2017, diabetes is one of top three cause of death among the non-communicable diseases. China (114.4 million), India (72.9 million) and U.S. (30.2 million) are top three economies having high prevalence of diabetes. Such high number of prevalence would offers an immense growth opportunity to the GLP-1 analogs market. This is also from the fact that approximately 212.4 million people worldwide are with undiagnosed diabetes. According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional anti-diabetic medication is propelling the growth of the market.

GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy) which is the major factor restraining growth of the market. Also, there is an issue of patient compliance. For instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic medications, which are taken orally in tablet form.

Glucagon-Like Peptide-1 Analogs Market Taxonomy:

On the basis of drug:

Exenatide
Liraglutide
Lixisenatide
Dulaglutide
Semaglutide
Albiglutide

On the basis of distribution channel:

Retail Pharmacy
Hospital pharmacy

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/glucagon-like-peptide-1-analogs-market-1252

Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo Nordisk in October 2017 received FDA approval for once-a-week GLP-1 analog semaglutide. GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits. Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due to high gastrointestinal side effects and hypersensitivity reactions.

Key players operating in the global Glucagon-like peptide-1 analogs market include Novo Nordisk, Eli-Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., Hoffmann-La Roche Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global Industry Insights - 2025 here

News-ID: 931630 • Views:

More Releases from Pharmaceutical Report By CMI

Angina Pectoris Treatment Market - Global Industry Insights, 2025
Angina Pectoris Treatment Market - Global Industry Insights, 2025
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest.
Angina Pectoris Treatment Market - Global Industry Insights 2025
Angina Pectoris Treatment Market - Global Industry Insights 2025
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest.
U.S. Opioids Market to Surpass US$ 18,985.4 Million Threshold by 2024
U.S. Opioids Market to Surpass US$ 18,985.4 Million Threshold by 2024
Opioids Crisis – Public Health Emergency Opioids are the class of drugs that include illicit drugs such as heroin, codeine, fentanyl, meperidine, methadone, morphine, hydrocodone, diphenoxylate, hydromorphone, methylphenidate, oxycodone, and oxymorphone, which are generally prescribed for pain management. Opioids are also prescribed for treatment of cough and diarrhea. According to the survey conducted by Center for Behavioral Health Statistics and Quality (CBHSQ), in 2015, out of 20.5 million about 2 million
Rx Medical Food Market to Surpass US$ 26,455.7 Million Threshold by 2025 Globally On Account of Increasing Regulatory Support
Rx Medical Food Market to Surpass US$ 26,455.7 Million Threshold by 2025 Globall …
Rx Medical Food – Let Medicine Be the Food Medical food is a category of products for dietary management or supportive therapy for specific disease or medical conditions such as pulmonary and metabolic disorders. Ingredients used in medical foods must have generally recognized as safe (GRAS) status, which is assigned to naturally found food materials. Medical food is different from nutritional food, dietary supplements, and prescription drugs. Medical food is protein-based,

All 5 Releases


More Releases for Analogs

Prostaglandin Analogs Market to Signify Strong Growth by 2023-2029
Prostaglandin Analogs Market size was valued at USD billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of % from 2024 to 2030. The Prostaglandin Analogs market is at the forefront of innovation in eye care, offering advanced treatments for glaucoma and ocular hypertension. Prostaglandin analogs are a class of medications that lower intraocular pressure (IOP) by increasing the outflow of aqueous humor from
Somatostatin Analogs Market Size: Industry Analysis, Segments, Drivers And Trend …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033 The Business Research Company offers in-depth market insights through Somatostatin Analogs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments. Market Size And Growth Forecast: The somatostatin analogs market size has grown strongly in recent years. It
Gamma-aminobutyric Acid Analogs Market - Unlocking Calm and Balance: Gamma-amino …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gamma-aminobutyric Acid Analogs Market. Gamma-aminobutyric Acid Analogs Market: https://www.growthplusreports.com/report/gammaaminobutyric-acid-analogs-market/9195 The Gamma-aminobutyric Acid Analogs Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the
Artificial Paintings Releases an NFT AI Artwork Collection With Physical Analogs
A tech company, Artificial Paintings, now offers their customers physical paintings - analogs of produced NFT. Customers can have a printed version of the purchased token. Artificial Paintings has started to trade its AI-generated digital artworks as NFTs. The company has already partnered with several NFT-marketplaces, where users can purchase non-fungible tokens. Recently, the tech company released a new collection of digital artworks , where every digital asset has a
Somatostatin Analogs Market : 2020 the Year on a Positive Note
Zion Market Research analysts forecast the latest report on "Global Somatostatin Analogs Market Set for Rapid Growth, to reach Value around USD 8.38 Billion by 2025", according to their latest report the Somatostatin Analogs Market report covers the overall and all-inclusive analysis of the Somatostatin Analogs Market with all its factors that have an impact on market growth. The Somatostatin Analogs Market's complete outline is crystal clear penned down in
Global Somatostatin Analogs Market Share to Hit USD 8.38 Billion by 2025
Latest Report Available at Zion Market Research, "Global Somatostatin Analogs Market Set for Rapid Growth, to reach Value around USD 8.38 Billion by 2025" provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth. The global Somatostatin Analogs Market research report is intended to help newbies as well as established market players to study and forecast this market at the